You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the ERLEADA (apalutamide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ERLEADA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ERLEADA

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02366494 ↗	Micro RNAs to Predict Response to Androgen Deprivation Therapy	Active, not recruiting	Medical College of Wisconsin		2015-04-29	Identify exosomal micro RNA that predict responses to ADT
NCT03009981 ↗	A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer	Recruiting	Janssen Research & Development, LLC	Phase 3	2017-03-06	This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
NCT03009981 ↗	A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer	Recruiting	Alliance Foundation Trials, LLC.	Phase 3	2017-03-06	This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
NCT03279250 ↗	Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer	Completed	Janssen Scientific Affairs, LLC	Phase 2	2017-10-13	This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or by blocking some of the enzymes needed for cell growth. Hormone therapy, using gonadotropin-releasing hormone analog, may fight prostate cancer by lowering the amount of testosterone the body makes. Giving apalutamide, gonadotropin-releasing hormone analog, and abiraterone acetate may work better in treating participants with prostate cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ERLEADA

Condition Name

Chart
Table

Condition Name for ERLEADA
Intervention	Trials
Prostate Adenocarcinoma	9
Prostate Cancer	7
Stage IVA Prostate Cancer AJCC v8	7
Stage IIIA Prostate Cancer AJCC v8	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ERLEADA
Intervention	Trials
Prostatic Neoplasms	20
Adenocarcinoma	6
Carcinoma	5
Hypersensitivity	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ERLEADA

Trials by Country

Map
Table

Trials by Country for ERLEADA
Location	Trials
United States	157
Canada	6
China	2
Australia	1
United Kingdom	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for ERLEADA
Location	Trials
Texas	11
California	10
Ohio	7
Pennsylvania	6
New York	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ERLEADA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ERLEADA
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	12
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ERLEADA
Clinical Trial Phase	Trials
Recruiting	12
Not yet recruiting	3
Suspended	3
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ERLEADA

Sponsor Name

Chart
Table

Sponsor Name for ERLEADA
Sponsor	Trials
National Cancer Institute (NCI)	10
Janssen Scientific Affairs, LLC	7
M.D. Anderson Cancer Center	6
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ERLEADA
Sponsor	Trials
Other	19
Industry	12
NIH	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.